SCHEMBL6292129

SCHEMBL6292129

Fc1ccc(Cc2cnc3[nH]c(C#CCc4ccccc4)nc3c2)cc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP13 P45452 1/20 0.38
CYP11B1 P15538 1/20 0.34
CYP11B2 P19099 1/20 0.34
MAPK14 Q16539 3/20 0.33
P2RX7 Q99572 1/20 0.32
LMNA P02545 1/20 0.32
MAPK1 P28482 1/20 0.32
CASP3 P42574 1/20 0.32
SENP7 Q9BQF6 1/20 0.32
SENP6 Q9GZR1 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
S1PR1 P21453 1/20 0.32
S1PR3 Q99500 1/20 0.32
GRM2 Q14416 2/20 0.32
GPER1 Q99527 1/20 0.31
NR3C1 P04150 1/20 0.31
HAO1 Q9UJM8 1/20 0.31
GRIN1 Q05586 3/20 0.31
GRIN2B Q13224 3/20 0.31
GALR3 O60755 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6292112 0.86 MMP13 (0.41) MMP13LMNA
SCHEMBL6288794 0.75 MMP13 (0.38) MMP13CYP11B1CYP11B2MAPK14P2RX7
SCHEMBL6289376 0.73 SMN1; SMN2 (0.45) MMP13LMNAL3MBTL1
SCHEMBL6292743 0.72 GPER1 (0.40) GRM2GPER1
SCHEMBL6289372 0.70 SNCA (0.35) MMP13CYP11B1CYP11B2GRIN1GRIN2B
SCHEMBL6288773 0.67 S1PR1 (0.44) MMP13CYP11B1CYP11B2S1PR1S1PR3
SCHEMBL6193088 0.65 MMP13 (0.46) MMP13MAPK14LMNAMAPK1CASP3
SCHEMBL6194527 0.65 MMP13 (0.46) MMP13MAPK14LMNAMAPK1CASP3
SCHEMBL576416 0.64 CALM1 (0.67) P2RX7LMNAMAPK1CASP3SENP7
SCHEMBL2982082 0.64 CALM1 (0.38) CYP11B1CYP11B2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6949651-B2 Fused bicyclic metalloproteinase inhibitors WARNER-LAMBERT COMPANY (US) 2005-09-27 US disclosed
US-20040034054-A1 Fused bicyclic metalloproteinase inhibitors LINCOLN FOODSERVICE PRODUCTS INC. 2004-02-19 US disclosed
WO-2004014375-A2 FUSED BICYCLIC METALLOPROTEINASE INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2004-02-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040034054-A1 Fused bicyclic metalloproteinase inhibitors MMP9, MMP1, MMP2 MMP13 9/4885CYP11B1 853/4885CYP11B2 1501/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.